Diagnostic difficulties with the diagnosis of small cell carcinoma of the lung
Small cell carcinoma of the lung (SCLC) is a well characterized form of lung cancer that is frequently already metastatic at diagnosis. Thus, patients with SCLC are usually treated with chemotherapy, and therefore emphasis has been placed on distinguishing that tumor from squamous cell carcinomas, large cell carcinomas and other pulmonary neoplasms that can more often be managed surgically. SCLC can be readily and accurately diagnosed in biopsy specimens or cytological preparations, but in selected cases, it can pose difficult diagnostic dilemmas. (Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - November 6, 2015 Category: Pathology Authors: Alberto M. Marchevsky, Mark R. Wick Source Type: research
Diagnostic Difficulties with the diagnosis of small-cell carcinoma of the lung
Small cell carcinoma of the lung (SCLC) is a well characterized form of lung cancer that is frequently already metastatic at diagnosis. Thus, patients with SCLC are usually treated with chemotherapy, and therefore emphasis has been placed on distinguishing that tumor from squamous cell carcinomas, large cell carcinomas and other pulmonary neoplasms that can more often be managed surgically. SCLC can be readily and accurately diagnosed in biopsy specimens or cytological preparations, but, in selected cases, it can pose difficult diagnostic dilemmas. (Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - November 6, 2015 Category: Pathology Authors: Alberto M. Marchevsky, Mark R. Wick Source Type: research
COVER (PMS 180&K) (p/u from previous issue w/updates)
(Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - November 1, 2015 Category: Pathology Source Type: research
MASTHEAD (p/u from previous issue)
(Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - November 1, 2015 Category: Pathology Source Type: research
EDITORIAL BOARD (p/u from previous issue)
(Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - November 1, 2015 Category: Pathology Source Type: research
TABLE OF CONTENTS (p/u from previous issue w/updates)
(Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - November 1, 2015 Category: Pathology Source Type: research
TOPICS (p/u from previous issue)
(Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - November 1, 2015 Category: Pathology Source Type: research
Introduction
Considering the growing trend for super-specialization amongst pathologists, few people now encounter ophthalmic specimens in their practices. The management of ocular tumors has progressed from ‘life salvage’ to ‘eye salvage’ or ‘vision salvage, ’ and histopathology plays an important role in determining therapeutic strategies and treatment protocols. In that context, it is essential that we be aware of the appropriate techniques, diagnostic clues, and recent advances for the treatment and prognostication of ophthalmic tumors. (Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - October 21, 2015 Category: Pathology Authors: Kaustubh Mulay Source Type: research
Introduction—Neuroendocrine neoplasms of the lung
Neuroendocrine neoplasms are a complex group of lesions that arise in the lung and other organs, and they may challenge anatomic pathologists with a variety of diagnostic problems. The origin of these tumors has been controversial historically. Pulmonary carcinoid tumors are thought to be derived from neuroendocrine cells distributed throughout the airway epithelium. On the other hand, small-cell carcinoma and large-cell neuroendocrine carcinoma have an origin that seems more akin to that of non-neuroendocrine carcinomas of the lung. (Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - October 16, 2015 Category: Pathology Authors: Alberto M. Marchevsky, Mark R. Wick Source Type: research
An update on ocular adnexal lymphoma
Ocular adnexal lymphoma (OAL) is a relatively common lesion in the practice of ocular oncology. Although OALs are usually primary tumors, secondary involvement of the ocular adnexae by systemic lymphoma is also possible. The clinical and radiological features of OAL are non-specific. Thorough morphological evaluation, aided by immunostaining, cytogenetic studies and molecular testing, are necessary to accurate diagnosis. (Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - October 16, 2015 Category: Pathology Authors: Kaustubh Mulay, Santosh G. Honavar Source Type: research
Retinoblastoma: An update
Retinoblastoma is the most common ocular malignancy in children, and is initiated by mutation of the RB1 gene. The tumor may be unilateral or bilateral and can be inherited. Overall survival, eye salvage, and preservation of vision are largely dependent on the stage of disease at presentation. Despite a recently-enhanced understanding of the etiology of retinoblastoma, the mortality associated with it remains high worldwide. This may relate to a continuing lack of awareness of the lesion by laypersons, and unavailability of modern treatment facilities. (Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - October 16, 2015 Category: Pathology Authors: Kushal S. Delhiwala, V.P. Indu, Kaustubh Mulay, Vikas Khetan Source Type: research
Diagnostic pathology issue about neuroendocrine Neoplasms of the lung
Neuroendocrine neoplasms are a complex group of neoplasms that arise in the lung and other organs and challenge practicing pathologists with a variety of diagnostic problems. The origin of these neoplasms has been somewhat controversial. Pulmonary carcinoid tumors are thought to be derived from neuroendocrine cells distributed throughout the airways epithelium while small cell carcinoma and large cell neuroendocrine carcinoma, high-grade neoplasms that exhibit similar neuroendocrine phenotype as carcinoid tumors appear to have an origin more akin to carcinomas of the lung. (Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - October 16, 2015 Category: Pathology Authors: Alberto M. Marchevsky, Mark R. Wick Source Type: research
What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?
Lung neuroendocrine tumors (NET) are currently classified in resection specimens according to four histological categories, namely typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCC). Diagnostic criteria have remained unchanged in the 2015 WHO classification, which has ratified the wide acceptance and popularity of such terminology in the pathologists’ and clinicians’ community. A unifying umbrella of NE morphology and differentiation has been recognized in lung NET, which has pushed to enter an unique box of invasive tumors along with diffuse idio...
Source: Seminars in Diagnostic Pathology - October 13, 2015 Category: Pathology Authors: Giuseppe Pelosi, Alessandra Fabbri, Mara Cossa, Angelica Sonzogni, Barbara Valeri, Luisella Righi, Mauro Papotti Source Type: research
Uveal melanoma
is the most common primary intraocular malignancy in adults. It is associated with a high rate of distant tumor spread and consequent mortality. Unlike retinoblastoma, for which treatment advances over the last few decades have resulted in a dramatic improvement in survival, outcomes for uveal melanoma patients remain unchanged. Despite improvement in local control of this tumor, roughly 50% of patients develop metastatic disease within 15 years. Delays in diagnosis and marked vascularity of this tumor may underlie that situation. (Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - October 7, 2015 Category: Pathology Authors: Seema Kashyap, Rachna Meel, Lata Singh, Mithalesh Singh Source Type: research
Clinical Trials Exploring the benefit of immunotherapy and radiation in Cancer treatment: A review of the past and A look into the future
Cancer immunotherapy is rapidly redefining the standard of cancer care. The role of radiation therapy in eliciting anti-tumoral immune response is also being actively investigated in combination with various immunotherapeutic agents to exploit potential synergy between the two modalities. In this review, we summarize the rationale and results of past and on-going clinical trials that combined the use of radiation therapy and immunogenic agents such as vaccines, cytokines, immune checkpoint inhibitors, co-stimulatory agonists, and myeloid activators. (Source: Seminars in Diagnostic Pathology)
Source: Seminars in Diagnostic Pathology - October 7, 2015 Category: Pathology Authors: Arash Naghavi, Peter Johnstone, Sungjune Kim Source Type: research
